|
Company:
|
EIDOS THERAPEUTICS, INC. (EIDX)
|
|
Form Type:
|
425
|
|
Filing Date:
|
1/13/2021
|
|
CIK:
|
0001731831
|
|
Address:
|
101 MONTGOMERY STREET, SUITE 2550
|
|
City, State, Zip:
|
SAN FRANCISCO, California 94104
|
|
Telephone:
|
650-391-9740
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$128.14
|
Change:
1.63 (1.29%)
|
Trade Time:
04:00 PM EST
|
Market Cap:
$4.98B
|
|
|
|
|
|
|
Description of Business
|
|
We are a clinical stage biopharmaceutical company focused on addressing the
large and growing unmet need in diseases caused by transthyretin, or TTR,
amyloidosis, or ATTR. We seek to treat this well-defined family of diseases by
targeting them at their collective source by stabilizing TTR. TTR is a protein
that occurs naturally in the form of a tetramer (a molecular structure
consisting of four identical subunits, or monomers) and performs multiple
beneficial roles, including the transport of essential hormones and vitamins.
Over 25 years of research have shown that ATTR is uniformly driven by
destabilization of the TTR tetramer, stemming from either specific gene
mutations or aging. TTR destabilization drives an irreversible dissociation of
the tetramer into monomers, which subsequently aggregate and deposit
predominantly in the heart and peripheral nervous system, leading to organ
damage, loss of organ function, and eventual death if left untreated.
|
|
|
|